Original article: Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: A randomized phase II study of the cancer and leukemia group B

Published

Journal Article

Summary: This randomized phase II study was designed to evaluate the activity of intravenous 6-thioguanine (6-TG) as a single agent and of the combination of cisplatin and 5-fluorouracil (5-Fu) modulated by oral lcucovorin (PFL) in patients with advanced non-small cell lung cancer (NSCLC). Eligible patients had measurable or evaluable stage III B or IV NSCLC, had not received prior chemotherapy and had a performance status of 0-2. Patients were randomized to treatment with intravenous 6-TG at 55 mg/m2 administered over 30 minutes for 5 consecutive days and repeated every 35 days, or PFL chemotherapy with cisplatin 100 mg/m2 on day 1, 5-FU 800 mg/m2/day as a continuous intravenous infusion over 5 days and oral leucovorin administered at 100 mg every 4 hours during the entire duration of the cisplatin and 5-FU infusions. PFL was repeated every three weeks. Ninety-five eligible patients were randomized, 46 to 6-TG and 49 to PFL. Response rates were 4% for 6-TG (95% confidence interval 0.5%-14.8%, 1 partial, and 1 complete response) and 29% (16.6%-43.3%) for PFL (all partial). The median time to treatment failure was 2 and 4 months, respectively, and the median survival times were 6 and 10 months, respectively. Toxicities with 6-TG were, generally, mild to moderate but severe or life-threatening granulocytopenia was observed in 21% of patients. With PFL, mucositis was dose-limiting, and 78% of patients had severe or life-threatening mucositis. This led to dose reduction of 5-FU and leucovorin during subsequent cycles or treatment termination in 82% of patients. We conclude that intravenous 6-TG has no significant activity at the dose and schedule used in this trial. PFL is an active but toxic regimen. © 1992 Kluwer Academic Publishers.

Duke Authors

Cited Authors

  • Vokes, EF; Lyss, AP; Herndon, JE; Cooper, B; Perry, MC; Vinciguerra, V; Mason-coughlin, K; Green, MR

Published Date

  • November 1, 1992

Published In

Volume / Issue

  • 3 / 9

Start / End Page

  • 727 - 732

International Standard Serial Number (ISSN)

  • 0923-7534

Citation Source

  • Scopus